Antihistamines as an early treatment for Covid-19
Background: Infection with SARs-COV-2 results in COVID-19 disease.Between March 2020 and August 2021, 468 COVID-19 patients confirmed by PCR or antigen test, in Yepes, Spain, received early treatment with antihistamines, adding azithromycin in selected cases. The primary endpoint is the hospitalizat...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-05-01
|
| Series: | Heliyon |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844023029791 |
| _version_ | 1797815624676671488 |
|---|---|
| author | Juan Ignacio Morán Blanco Judith A. Alvarenga Bonilla Philip Fremont-Smith Karina Villar Gómez de las Heras |
| author_facet | Juan Ignacio Morán Blanco Judith A. Alvarenga Bonilla Philip Fremont-Smith Karina Villar Gómez de las Heras |
| author_sort | Juan Ignacio Morán Blanco |
| collection | DOAJ |
| description | Background: Infection with SARs-COV-2 results in COVID-19 disease.Between March 2020 and August 2021, 468 COVID-19 patients confirmed by PCR or antigen test, in Yepes, Spain, received early treatment with antihistamines, adding azithromycin in selected cases. The primary endpoint is the hospitalization rate of COVID-19 patients, and the secondary endpoints are ICU admission and mortality rates. All endpoints are compared with the official Spanish rates during the time period of the study.There were 20 hospital admissions (hospitalization rate 4,3%), 5 ICU admissions (ICU admission rate 1,1%) and 3 deaths (fatality rate of 0,6%). No patients in the study required follow up treatment, which suggest they did not develop long COVID. Results from this retrospective trail indicate that early treatment of SARS-COV-2 positive patients with antihistamines may reduce the odds of hospitalization (OR: 0.490, CI: 0.313–0.767, p-value: 0.001). Randomized controlled clinical trials are needed to further evaluate the effects of early antihistamine treatment of SARS-CoV-2 patients to prevent hospitalization, ICU admission, mortality and long-covid. |
| first_indexed | 2024-03-13T08:25:37Z |
| format | Article |
| id | doaj.art-3a58432c10f74094b269452068404abc |
| institution | Directory Open Access Journal |
| issn | 2405-8440 |
| language | English |
| last_indexed | 2024-03-13T08:25:37Z |
| publishDate | 2023-05-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Heliyon |
| spelling | doaj.art-3a58432c10f74094b269452068404abc2023-05-31T04:45:29ZengElsevierHeliyon2405-84402023-05-0195e15772Antihistamines as an early treatment for Covid-19Juan Ignacio Morán Blanco0Judith A. Alvarenga Bonilla1Philip Fremont-Smith2Karina Villar Gómez de las Heras3Servicio de Salud de Castilla-La Mancha (SESCAM), Toledo, Spain; Centro de Salud de Yepes, Toledo, SpainServicio de Salud de Castilla-La Mancha (SESCAM), Toledo, Spain; Centro de Salud de Yepes, Toledo, SpainMassachusetts Institute of Technology Lincoln Laboratory, Lexington, MA, USAServicio de Salud de Castilla-La Mancha (SESCAM), Toledo, Spain; Gerencia de Urgencias, Emergencias y Transporte Sanitario, Toledo, Spain; Universidad de Alcalá de Henares, Facultad de Medicina y Ciencias de la Salud, Alcalá de Henares, Madrid, Spain; Corresponding author. Gerencia de Urgencias, Emergencias y Transporte Sanitario Servicio de Salud de Castilla-La Mancha, C/ Huérfanos Cristinos, 5, 45071, Toledo, Spain.Background: Infection with SARs-COV-2 results in COVID-19 disease.Between March 2020 and August 2021, 468 COVID-19 patients confirmed by PCR or antigen test, in Yepes, Spain, received early treatment with antihistamines, adding azithromycin in selected cases. The primary endpoint is the hospitalization rate of COVID-19 patients, and the secondary endpoints are ICU admission and mortality rates. All endpoints are compared with the official Spanish rates during the time period of the study.There were 20 hospital admissions (hospitalization rate 4,3%), 5 ICU admissions (ICU admission rate 1,1%) and 3 deaths (fatality rate of 0,6%). No patients in the study required follow up treatment, which suggest they did not develop long COVID. Results from this retrospective trail indicate that early treatment of SARS-COV-2 positive patients with antihistamines may reduce the odds of hospitalization (OR: 0.490, CI: 0.313–0.767, p-value: 0.001). Randomized controlled clinical trials are needed to further evaluate the effects of early antihistamine treatment of SARS-CoV-2 patients to prevent hospitalization, ICU admission, mortality and long-covid.http://www.sciencedirect.com/science/article/pii/S2405844023029791SARS-CoV-2CoronavirusAzithromycinAntihistamines |
| spellingShingle | Juan Ignacio Morán Blanco Judith A. Alvarenga Bonilla Philip Fremont-Smith Karina Villar Gómez de las Heras Antihistamines as an early treatment for Covid-19 Heliyon SARS-CoV-2 Coronavirus Azithromycin Antihistamines |
| title | Antihistamines as an early treatment for Covid-19 |
| title_full | Antihistamines as an early treatment for Covid-19 |
| title_fullStr | Antihistamines as an early treatment for Covid-19 |
| title_full_unstemmed | Antihistamines as an early treatment for Covid-19 |
| title_short | Antihistamines as an early treatment for Covid-19 |
| title_sort | antihistamines as an early treatment for covid 19 |
| topic | SARS-CoV-2 Coronavirus Azithromycin Antihistamines |
| url | http://www.sciencedirect.com/science/article/pii/S2405844023029791 |
| work_keys_str_mv | AT juanignaciomoranblanco antihistaminesasanearlytreatmentforcovid19 AT judithaalvarengabonilla antihistaminesasanearlytreatmentforcovid19 AT philipfremontsmith antihistaminesasanearlytreatmentforcovid19 AT karinavillargomezdelasheras antihistaminesasanearlytreatmentforcovid19 |